Saturday 17 October 2026
Export AMLX’s income statement to Excel — free account
Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
26.34
1.31
−4.74%
Follow AMLX
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 5 | 6 | 3 | — |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 20.51 | 0.00 | — |
P/S ratio |
— | 0.00 | 0.00 | 0.00 | 2.64 | 2.95 | — |
Altman Z-Score |
— | — | — | 23.63 | 8.11 | (2.95) | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 94.26 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | (30.71) | 0.68 | 6.25 | 8.85 | (9.69) | — |
Beneish M-Score |
— | — | — | — | 13.35 | — | — |
P/Operating CF |
— | (4.21) | (4.21) | (42.35) | 74.27 | (4.37) | — |
P/B ratio |
— | 0.00 | 0.00 | 6.18 | 2.32 | 1.56 | — |
Price to Tangible BV |
— | 0.00 | 0.00 | 6.18 | 2.32 | 1.56 | — |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | 1.67 | 0.94 | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 21.25 | 0.00 | — |
EV/Operating CF |
— | (0.33) | (0.33) | (9.78) | 53.41 | (0.49) | — |
EV/FCF |
— | (0.32) | (0.32) | (9.64) | 59.61 | (0.40) | — |
Quick Ratio |
— | 1.76 | 5.53 | 7.77 | 5.01 | 6.23 | 13.98 |
Current Ratio |
— | 1.86 | 6.03 | 8.20 | 5.66 | 6.67 | 14.27 |
Net Debt/EBITDA |
— | 0.29 | 1.16 | 1.71 | (12.40) | 0.55 | 2.00 |
Debt/Assets |
0.00% | 10.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.09 | 0.00 | 0.09 | 0.84 | 0.25 | 0.00 |
Operating CF/Net income |
— | 0.87 | 0.85 | 0.91 | 0.24 | 0.56 | 0.85 |
Capex/Depreciation |
— | (151.00) | (2.04) | 1.61 | 0.14 | 4.06 | 0.03 |
Interest Coverage |
— | (17.05) | — | — | — | — | — |
| — | 0.00% | 80.71% | (209.43%) | 12.73% | (100.88%) | (61.59%) | |
| — | (599.55%) | (146.90%) | (79.82%) | 10.84% | (84.87%) | (55.00%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 39.07% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (654.08%) | (99.89%) | (58.67%) | 12.79% | (186.28%) | (48.04%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 251.31 | 38.39 | 1.87 | 0.00 |
Research and Development Expense of Revenue |
— | 3,783.69% | 15,452.63% | 420.38% | 33.66% | 119.13% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 2,317.08% | 13,660.70% | 571.88% | 49.47% | 130.86% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 37.38% | 1,100.35% | 97.68% | 9.76% | 37.81% | 0.00% |
Graham Net Nets |
— | 0.74 | 0.74 | 0.16 | 0.38 | 0.62 | — |
Graham Number |
— | 0.00 | 83.03 | 0.00 | 10.29 | 0.00 | — |
Earnings Yield |
— | (73.88%) | (73.88%) | (9.53%) | 4.88% | (117.46%) | — |
Free Cash Flow Yield |
— | (63.15%) | (63.15%) | (8.67%) | 1.06% | (79.20%) | — |
Revenue per Share |
— | 0.11 | 0.04 | 0.38 | 5.66 | 1.28 | 0.00 |
Operating CF per Share |
— | (6.04) | (11.36) | (3.07) | 0.18 | (2.46) | (1.30) |
Capex per Share |
— | (0.02) | (0.05) | (0.04) | (0.02) | (0.53) | 0.00 |
Free Cash Flow per Share |
— | (6.06) | (11.41) | (3.12) | 0.16 | (2.99) | (1.31) |
Cash per Share |
— | 2.12 | 14.59 | 5.93 | 5.52 | 2.59 | 3.35 |
Shareholders Equity per Share |
— | 0.88 | 13.39 | 5.82 | 6.45 | 2.42 | 3.23 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.88 | 13.39 | 5.82 | 6.45 | 2.42 | 3.23 |
Free Cash Flow |
— | (36.85) | (75.15) | (182.40) | 10.68 | (204.01) | (123.48) |
Working Capital |
— | 6.31 | 87.56 | 335.52 | 382.62 | 161.03 | 300.98 |
Capital Expenditures |
— | (0.15) | (0.35) | (2.53) | (1.24) | (36.36) | (0.14) |
Net Current Asset Value |
— | 4.87 | 87.52 | 331.29 | 380.64 | 160.56 | 296.29 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 16.41 | 0.00 | — |
Capex to Sales |
— | 0.23 | 1.24 | 0.11 | 0.00 | 0.42 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 25.94 | 0.00 | — |
| Other line items | |||||||
Depreciation/Fixed assets |
— | 0.01 | 0.37 | (0.60) | (3.30) | (9.32) | (16.13) |
Cash ROIC |
— | (187.63%) | (40.78%) | (26.53%) | 1.33% | (59.78%) | (19.84%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 13.76 | 4.31 | 0.00 |
Accounts Payable Turnover |
— | — | 0.00 | 0.56 | 1.80 | 9.97 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 1.06 | 0.00 | — |
Average Days of Payables |
— | 0.00 | 0.00 | 763.05 | 316.51 | 8.61 | 0.00 |
Days of Inventory on Hand |
— | — | — | 1,191.34 | 549.82 | 0.00 | — |
Average Receivables |
— | — | — | — | 27.68 | 20.25 | 0.27 |
Average Payables |
— | — | 3.99 | 5.31 | 14.16 | 12.50 | 3.23 |
Average Inventory |
— | — | — | — | 24.05 | — | — |
Average Assets |
— | 7.05 | 59.86 | 248.53 | 454.45 | 355.54 | 263.14 |
Average Common Equity |
— | — | (108.95) | 94.72 | 387.02 | 299.10 | 235.01 |
Columns are period end dates